Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma

Chinese Journal of Cancer

Volumn 32, Issue 3, 2013, Pages 141-148

  Li, Jian Jun ^a   Pan, Ke ^a   Gu, Mo Fa ^a   Chen, Min Shan ^a   Zhao, Jing Jing ^a   Wang, Hui ^a   Liang, Xiao Ting ^a   Sun, Jian Cong ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Hepatocellular carcinoma; Prognosis; Soluble MICA

Indexed keywords

ANTINEOPLASTIC AGENT; CD56 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D; SOLUBLE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I MOLECULE A; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CHEMOEMBOLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME;

ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN;

EID: 84874834258     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10025     Document Type: Article

References (27)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003,362:1907-1917.
2. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med, 2003,139:817-823.
3. Bruix J. Treatment of hepatocellular carcinoma. Hepatology, 1997,25:259-262.
4. Wörn s MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis, 2010,42:S302-S309.
5. Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci, 2010, 55:2744-2755.
6. Robinson J, Perez-R odriguez M, Waller MJ, et al. MICA sequences 2000. Immunogenetics, 2001, 53:150-169.
7. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 2002, 62: 6178-6186.
8. Zhang C, Zhang J, Wei H, et al. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity? Int Immunopharmacol, 2005,5:1099-1111.
9. Jinushi M, Takehara T, Tatsumi T, et al. Impairment of natural killer cell and dendritic cell functions by soluble form of MHC class I-related chain A in advanced human hepatocellular carcinoma. J Hepatol, 2005,43:1013-1020.
10. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 2002,419:734-738.
11. Li K, Mandai M, Hamanishi J, et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother, 2009,58:641-652.
12. Tamaki S, Sanefuzi N, Kawakami M, et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol, 2008,69:88-93.
13. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain- related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA, 2008,105:1285-1290.
14. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol, 2002,20:1527-1536.
15. AJCC. AJCC Cancer staging manual. 6th edition. New York, USA: Springer, 2002:66-72.
16. Farnsworth N, Fagan SP, Berger DH, et al. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg, 2004,188:580-583.
17. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science, 1999, 285: 727-729.
18. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol, 2005,25:534-540.
19. Jinushi M, Takehara T, Tatsumi T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer, 2003, 104: 354-361.
20. Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest, 2004,114:560-568.
21. Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or release of NKG2D ligands as an immune evasion strategy of human neuroblastoma. Neoplasia, 2004, 6: 558-568.
22. Armeanu S, Krusch M, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res, 2008,14:3520-3528.
23. Salih HR, Rammensee HG, Steinle A. Downregulation of MICA on human tumors by proteolytic shedding. J Immunol, 2003, 1699: 4098-4102.
24. Madjd Z, Spendlove I, Moss R, et al. Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun, 2007,7:17-26.
25. Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest, 2004,114:560-568.
26. Arreygue-Garcia N, Daneri-Navarro A, del Toro-Arreola A, et al. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer, 2008, 8: 1-10.
27. Kohga K, Takehara T, Tatsumi T, et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver disease and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci, 2008, 99: 1643-1649.